Angehefteter Tweet
The first day of my lab at UTSW nephrology. Very much excited to see how it goes !!
English
Yoshiharu Muto
312 posts
Yoshiharu Muto
@Yoshi_MutoLab
Assistant Professor @UTSWNephrology | Focusing on single cell analysis / epigenetics / metabolism, to identify therapeutic targets in kidney diseases
Dallas, TX Beigetreten Mayıs 2018
357 Folgt413 Follower
Yoshiharu Muto retweetet
Polycystic kidney disease is the most common monogenic cause of kidney failure and affects over 10 million individuals. We've known most PKD is caused by mutations in PKD1 for over 30 years. But how PKD1 prevents disease has remained mysterious, limiting effective therapy.
English
@Shumeng's beautiful work, intersting concept about podocyte mechanoresponses to shear stress, now in BioRxiv:
biorxiv.org/content/10.648…
English
Very pleased to share that our study on epithelial responses to T-cell–mediated rejection is published today in Nature Communications. Quite a journey! 😅nature.com/articles/s4146…
English
English
Yoshiharu Muto retweetet
🧬 In #ADPKD, reduced PKD1 drives cyst growth and kidney failure.
We previously discovered a 55bp cis-repressive element in its 3'UTR.
We now identify the six critical bases—the miR-17 motif—whose disruption or masking restores PKD1 and slows disease.
🔗 biorxiv.org/content/10.110…
English
@samirparikhmd @hansul @UTSWMedCenter Thank you again Samir for the great introduction today! I appreciate your continued support!!
English
Yoshiharu Muto retweetet
Congratulations to @Yoshi_MutoLab and @hansul on their outstanding presentations today at the @UTSWMedCenter New Faculty Forum!
English
Yoshiharu Muto retweetet
Check out our latest manuscript where we generate a cross model single cell and spatial atlas of mouse PKD!
A cross model spatial and single-cell atlas reveals the conserved involvement of osteopontin in polycystic kidney disease | bioRxiv biorxiv.org/content/10.110…
English
More to come if I ever learn the art of tweetorials.
For now, I'm so grateful to 1st author Vivian Huang @BIDMChealth and our collaborators from @harvardmed @HopkinsMedicine @YaleMed @UCSFMedicine @TuftsMedicalCtr @UW @BUMedicine...and @ScienceMagazine 🙏
Jochen Reiser MD PhD@JochenReiser
Congrats to @samirparikhmd and team for a breakthrough paper in @ScienceMagazine showing that somatically acquired heteroplasmic mtDNA mutations are a cause of chronic kidney disease and are functionally reversible. @ASNKidney @the_asci 👇👇
English
@samirparikhmd @UTSWNephrology @BIDMChealth @harvardmed @HopkinsMedicine @YaleMed @UCSFMedicine @TuftsMedicalCtr @UW @BUMedicine @ScienceMagazine Congratulations 🎊🎉 Beautiful work!!
English
English
Yoshiharu Muto retweetet
Thrilled to share our work and truly honored to share senior autorship with @FabiolaTerzi ! Thanks @ScienceTM for publishing our work ! science.org/doi/10.1126/sc…
English
Happy to share our recent work: TSC-associated tubulointerstitial kidney disease.
kireports.org/article/S2468-…
Thanks to @KIReports for publishing our work !
English
Happy to announce that our research paper was recently published. Dapagliflozin improved renal function, fibrosis, cell senescence, lipid accumulation, and survival in mice with Alport syndrome.@slunephrons
AJP Renal@AJPRenal
There's news about treating #AlportSyndrome in this #ArticleinPress from @slunephrons, Dapagliflozin in addition to Ramipril Ameliorates Kidney Disease Progression in Mice with Alport Syndrome (Kana N. Miyata et al.): ow.ly/ZZ7I50Wh3Zm
English
Thank you @ASNKidney! Our lab is very grateful to receive the 2025 Carl W. Gottschalk Research Scholar Grant. Read more about the work here: kidneycure.org/pages/qa.aspx?….
English
@Zimmermk1986 @OuhscN Congratulations 🎊🎉 Richly deserved!
English
Excited to announce that I am officially getting promoted to Associate Professor at @OuhscN effective July 1, 2025!! A huge thank you to everyone who wrote me a letter of support for promotion!
English
Check out our new paper in Pediatric Nephrology assessing NAD Biosynthesis metabolites in pediatric AKI!
Pediatric Nephrology@Ped_Neph
AKI is highly prevalent among hospitalized children, but there is no treatment. Read this Original Article on pediatric AKI associated w/impairment in nicotinamide adenine dinucleotide (NAD+) metabolism. @AmandaJClarkMD link.springer.com/article/10.100…
English
@Vishal_D_Patel @Boletta_Lab Congratulations 🎉🍾 Would be a wonderful moment for a physician-scientist to see the molecule you have studied go close to the clinical side!!
English
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure finance.yahoo.com/news/novartis-…
English
The collaborative spirit among ADPKD researchers and patients is the engine behind innovative therapies. Thank you, @MuellerRom, for the kind words and the support!
For me, it's meaningful validation of our work and the rewarding, if unpredictable, path of a physician-scientist.
Roman-Ulrich Müller@MuellerRom
Great News! This is not only a great opportunity for ADPKD but can well be a game-changer towards nucleic acid therapeutics in the kidney and miRNA therapeutics in general. Congratulations to the whole Regulus team but specifically to @Vishal_D_Patel 🧵 below
English